Alloy Therapeutics is a biotechnology ecosystem company on a mission to democratize access to foundational drug discovery technologies and services. Founded in 2017, Alloy empowers the global scientific community - from academic labs to biopharma giants - to discover and develop better biologics together. The company has built an integrated platform spanning multiple therapeutic modalities: antibodies and bispecifics, TCR mimics, genetic medicines, and cell therapies. By embedding AI/ML directly into discovery workflows and combining it with one of the industry's largest proprietary experimental datasets, Alloy shortens design cycles, improves prediction accuracy, and enables partners to move from concept to human data with unprecedented speed and capital efficiency.
What truly sets Alloy apart is its commitment to open access and reinvestment. With 100% of profits invested back into future innovation, the company continuously pushes the boundaries of science to deliver groundbreaking solutions. Alloy's 100+ scientists across global labs in Waltham, MA; Athens, GA; Cambridge, UK; Basel, Switzerland; and Fujisawa, Japan bring deep expertise to tackle the hardest drug discovery challenges. The company operates with a partner-first philosophy, offering flexible collaboration models that put the best drugs to patients faster - because at Alloy, they believe the industry should compete on therapeutic outcomes, not exclusive access to platforms.